Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
HI TECH PHARMACAL CO INC (HITK)
|
Add to portfolio |
|
|
|
| Price: |
$36.31
| | Metrics |
| OS: |
13.9
|
M
| |
4
|
% ROE
|
| Market cap: |
$505
|
M
| |
-39
|
% ROIC
|
|
Net cash:
|
$86.4
|
M
| |
$6.22
|
per share
|
|
EV:
|
$419
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($140)
|
M
| |
|
|
|
EBIT
|
($148)
|
M
| |
|
|
| EPS |
$0.66
| |
54.7
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Apr-30-13 | Apr-30-12 | Apr-30-11 | Apr-30-10 | Apr-30-09 | Apr-30-08 | Apr-30-07 | Apr-30-06 |
| Revenues | 232.4 | 230.0 | 190.8 | 159.3 | 101.8 | 62.0 | 58.9 | 78.0 |
| Revenue growth | 1.0% | 20.5% | 19.8% | 56.6% | 64.1% | 5.3% | -24.5% | 15.3% |
| Cost of goods sold | 117.3 | 100.8 | 83.3 | 68.6 | 53.8 | 40.5 | 35.7 | 35.8 |
| Gross profit | 115.1 | 129.2 | 107.6 | 90.8 | 47.9 | 21.5 | 23.2 | 42.2 |
| Gross margin | 49.5% | 56.2% | 56.4% | 57.0% | 47.1% | 34.7% | 39.4% | 54.1% |
| Selling, general and administrative | 53.6 | 44.7 | 36.7 | 41.9 | 30.6 | 22.6 | 23.9 | 23.2 |
| Research and development | 17.3 | 12.3 | 9.4 | 7.3 | 7.4 | | | |
| EBITA | -62.8 | 18.2 | 25.0 | 3.7 | 14.8 | -6.9 | -4.1 | 17.6 |
| EBITA margin | -27.0% | 7.9% | 13.1% | 2.3% | 14.5% | -11.1% | -6.9% | 22.5% |
| Amortization of intangibles | 6.7 | 5.3 | 2.4 | 1.2 | | | | |
| EBIT | -69.6 | 12.9 | 22.6 | 2.5 | 14.8 | -6.9 | -4.1 | 17.6 |
| EBIT margin | -29.9% | 5.6% | 11.9% | 1.6% | 14.5% | -11.1% | -6.9% | 22.5% |
| Pre-tax income | 22.9 | 70.8 | 64.8 | 46.1 | 14.8 | -6.9 | -4.0 | 17.6 |
| Income taxes | 6.6 | 22.5 | 21.1 | 14.5 | 5.7 | 0.0 | 0.0 | 6.1 |
| Tax rate | 29.0% | 31.7% | 32.5% | 31.4% | 38.4% | 0.0% | 0.0% | 34.9% |
| Earnings from continuing ops | 16.3 | 48.4 | 43.7 | 31.6 | 9.1 | | | 11.5 |
| Earnings from discontinued ops | | | | | 0.7 | | | |
| Net income | 16.3 | 48.4 | 41.5 | 31.1 | 9.8 | 0.0 | 0.0 | 11.5 |
| Net margin | 7.0% | 21.0% | 21.7% | 19.5% | 9.6% | 0.0% | 0.0% | 14.7% |
| |
| Diluted EPS | $1.19 | $3.59 | $3.36 | $2.54 | $0.78 | $0.00 | $0.00 | $0.85 |
| Shares outstanding (diluted) | 13.6 | 13.5 | 13.0 | 12.4 | 11.7 | 11.4 | 11.9 | 13.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|